Lysin therapy for Staphylococcus aureus and other bacterial pathogens

Current Topics in Microbiology and Immunology

Volumn 409, Issue , 2017, Pages 529-540

  Fischetti, Vincent A ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; LYSIN; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; BACILLUS ANTHRACIS; BACILLUS CEREUS; BACILLUS MEGATERIUM; BACILLUS THURINGIENSIS; BACTERIAL VIRULENCE; BIOFILM; CLOSTRIDIUM PERFRINGENS; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SPECIFICITY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GROUP B STREPTOCOCCAL PNEUMONIA; HUMAN; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS EQUI; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SUIS; STREPTOCOCCUS UBERIS; BACTERIOPHAGE;

ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; STAPHYLOCOCCUS AUREUS;

EID: 85041345564     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2015_5005     Document Type: Chapter

References (47)

1. Ahmed KB, Warner SL, Chen A, Gourley ES, Liu X, Vankayalapati H, Nussenzveig R, Prchal JT, Bearss DJ, Parker CJ (2011) In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2. Exp Hematol 39(1):14–25
2. Andersson DI, Hughes D (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8(4):260–271
3. Barrett FF, McGehee RF Jr, Finland M (1968) Methicillin-resistant Staphylococcus aureus at Boston City Hospital. Bacteriologic and epidemiologic observations. N Engl J Med 279 (9):441–448
4. Centers for Disease Control and Prevention (1999) Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus–Minnesota and North Dakota, 1997–1999. JAMA 282(12):1123–1125
5. Cheng Q, Nelson D, Zhu S, Fischetti V (2005) Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 49(1):111–117
6. Clyne M, Birkbeck TH, Arbuthnott JP (1992) Characterization of staphylococcal Y-lysin. J Gen Microbiol 138:923–930
7. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA (2010) Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54(4):1603–1612
8. Djurkovic S, Loeffler JM, Fischetti VA (2005) Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob Agents Chemother 49:1225–1228
9. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P (2005) Therapeutic effects of bacteriophage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrob Agents Chemother 49(11):4789–4792
10. Fenton M, Ross P, McAuliffe O, O’Mahony J, Coffey A (2010) Recombinant bacteriophage lysins as antibacterials. Bioeng Bugs 1(1):9–16
11. Fischetti VA (2010) Bacteriophage endolysins: a novel anti-infective to control gram-positive pathogens. Int J Med Microbiol 300(6):357–362
12. Fischetti VA, Nelson D, Schuch R (2006) Reinventing phage therapy: are the parts greater than the sum? Nat Biotechnol 24(12):1508–1511
13. Garcia P, Garcia E, Ronda C, Tomasz A, Lopez R (1983) Inhibition of lysis by antibody against phage-associated lysin and requirement of choline residues in the cell wall for progeny phage release in Streptococcus pneumoniae. Curr Microbiol 8:137–140
14. Gilmer DB, Schmitz JE, Euler CW, Fischetti VA (2013) Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother
15. Herold BC, Immergluck LC, Maranan MC, Lauderdale DS, Gaskin RE, Boyle-Vavra S, Leitch CD, Daum RS (1998) Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA J Am Med Assoc 279(8):593–598
16. Huang YT, Hsiao CH, Liao CH, Lee CW, Hsueh PR (2008) Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan. J Clin Microbiol 46(3):1132–1136
17. Jervis EJ, Haynes CA, Kilburn DG (1997) Surface diffusion of cellulases and their isolated binding domains on cellulose. J Biol Chem 272(38):24016–24023
18. Klein E, Smith DL, Laxminarayan R (2007) Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis 13 (12):1840–1846
19. Lai MJ, Lin NT, Hu A, Soo PC, Chen LK, Chen LH, Chang KC (2011) Antibacterial activity of Acinetobacter baumannii phage varphiAB2 endolysin (LysAB2) against both gram-positive and gram-negative bacteria. Appl Microbiol Biotechnol 90(2):529–539
20. Laupland KB, Ross T, Gregson DB (2008) Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000–2006. J Infect Dis 198(3):336
21. Li M, Diep BA, Villaruz AE, Braughton KR, Jiang X, DeLeo FR, Chambers HF, Lu Y, Otto M (2009) Evolution of virulence in epidemic community-associated methicillin-resistant Staphylococcus aureus. Proc Natl Acad Sci USA 106(14):5883–5888
22. Loeffler JM, Fischetti VA (2003) Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains. Antimicrob Agents Chemother 47:375–377
23. Loeffler JM, Nelson D, Fischetti VA (2001) Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294(5549):2170–2172
24. Loeffler JM, Djurkovic S, Fischetti VA (2003) Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun 71(11):6199–6204
25. Loessner MJ, Maier SK, Daubek-Puza H, Wendlinger G, Scherer S (1997) Three Bacillus cereus bacteriophage endolysins are unrelated but reveal high homology to cell wall hydrolases from different bacilli. J Bacteriol 179(9):2845–2851
26. Loessner MJ, Kramer K, Ebel F, Scherer S (2002) C-terminal domains of Listeria monocytogenes bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. Mol Microbiol 44(2):335–349
27. Lood R, Winer BY, Pelzek AJ, Diez-Martinez R, Thandar M, Euler CW, Schuch R, Fischetti VA (2015) Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother 59 (4):1983–1991
28. Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339(8):520–532
29. Manoharadas S, Witte A, Blasi U (2009) Antimicrobial activity of a chimeric enzybiotic towards Staphylococcus aureus. J Biotechnol 139(1):118–123
30. Matsuzaki S, Rashel M, Uchiyama J, Sakurai S, Ujihara T, Kuroda M, Ikeuchi M, Tani T, Fujieda M, Wakiguchi H, Imai S (2005) Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 11(5):211–219
31. Miller LG, Perdreau-Remington F, Rieg G, Mehdi S, Perlroth J, Bayer AS, Tang AW, Phung TO, Spellberg B (2005) Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 352(14):1445–1453
32. Nelson D, Loomis L, Fischetti VA (2001) Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 98(7):4107–4112
33. O’Flaherty S, Coffey A, Meaney W, Fitzgerald GF, Ross RP (2005) The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J Bacteriol 187(20):7161–7164
34. O’Flaherty S, Ross RP, Coffey A (2009) Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev 33(4):801–819
35. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S, Yagyu K, Muraoka A, Sugai M, Hiramatsu K, Honke K, Matsuzaki S (2007) Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. J Infect Dis 196(8):1237–1247
36. Schmelcher M, Powell AM, Camp MJ, Pohl CS, Donovan DM (2015) Synergistic streptococcal phage lambdaSA2 and B30 endolysins kill streptococci in cow milk and in a mouse model of mastitis. Appl Microbiol Biotechnol
37. Schuch R, Nelson D, Fischetti VA (2002a) A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418(6900):884–889
38. Schuch R, Pelzek AJ, Raz A, Euler CW, Ryan PA, Winer BY, Farnsworth A, Bhaskaran SS, Stebbins CE, Xu Y, Clifford A, Bearss DJ, Vankayalapati H, Goldberg AR, Fischetti VA (2013) Use of a bacteriophage lysin to identify a novel target for antimicrobial development. PLoS ONE 8(4):e60754
39. Schuch R, Lee HM, Schneider BC, Sauve KL, Law C, Khan BK, Rotolo JA, Horiuchi Y, Couto DE, Raz A, Fischetti VA, Huang DB, Nowinski RC, Wittekind M (2014) Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-Induced murine bacteremia. J Infect Dis 209 (9):1469–1478
40. Sonstein SA, Hammel JM, Bondi A (1971) Staphylococcal bacteriophage-associated lysin: a lytic agent active against Staphylococcus aureus. J Bacteriol 107(2):499–504
41. Tiemersma EW, Bronzwaer S, Lyytikainen O, Degener JE, Schrijnemakers P, Bruinsma N, Monen J, Witte W, Grundman H (2004) Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002. Emerg Infect Dis 10(9):1627–1634
42. Wang IN, Smith DL, Young R (2000) Holins: the protein clocks of bacteriophage infections. Annu Rev Microbiol 54:799–825
43. Wang IN, Deaton J, Young R (2003) Sizing the holin lesion with an endolysin-beta-galactosidase fusion. J Bacteriol 185(3):779–787
44. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL (2005) The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5 (12):751–762
45. White A, Smith J (1963) Nasal reservoir as the source of extranasal staphylococci. Antimicrob Agents Chemother (Bethesda) 161:679–683
46. Woodford N, Ellington MJ (2007) The emergence of antibiotic resistance by mutation. Clin Microbiol Infect 13(1):5–18
47. Yoong P, Nelson D, Schuch R, Fischetti VA (2004) Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium. J Bacteriol 186:4808–4812